Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase NA 1Phase EARLY_PHASE1 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Leiomyoma 2Women With Mutations in the Breast Cancer Susceptibility Genes BRCA1,2 1Uterine Hemorrhage 1Prostatic Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Stromal Tumors 1Endometrial Neoplasms 1Cushing Syndrome 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1ACTH Syndrome, Ectopic 1

Interventions

Trastuzumab 304Paclitaxel 257Cyclophosphamide 251Docetaxel 238Capecitabine 176Letrozole 163Carboplatin 163Fulvestrant 145Doxorubicin 145Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 89Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 45Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × Mifepristone × Clear all
NCT06099769 2026-02-25

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
201 enrolled
Breast

Breast Neoplasms

NCT03225547 2025-12-23

Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

University of Chicago

Phase 2 Terminated
24 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02788981 2025-06-10

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

University of Chicago

Phase 2 Active not recruiting
29 enrolled 11 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡